Real‐world effectiveness of first‐line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy
Open Access
- 18 July 2024
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 113 (5) , 623-630
Abstract
Background: First‐line treatment in patients with acute myeloid leukemia (AML) unfit for intensive therapy is the combination of a hypomethylating agent (HMA) with venetoclax (VEN). However, retrospective data confirming the benefits of this regimen outside of clinical trials have shown conflicting results.Methods: We performed a multicenter retrospective analysis of outcomes with first‐line HMA–VEN versus HMA in AML patients unfit for intensive chemotherapy.Results: A total of 213 patients were included from three German hospitals (125 HMA–VEN, 88 HMA). Median overall survival in the HMA–VEN cohort was 7.9 months (95% confidence interval [CI], 5.1–14.7) versus 4.9 months (3.1–7.1) with HMA. After 1 year, 42% (95% CI, 33–54) and 19% (12–30) of patients were alive, respectively (hazard ratio [HR] for death, 0.64; 95% CI, 0.46–0.88). After adjusting for clinical and molecular baseline characteristics, treatment with HMA–VEN remained significantly associated with both prolonged survival (HR, 0.48; 95% CI, 0.29–0.77) and time to next treatment (HR, 0.63; 95% CI, 0.47–0.85). Patients who achieved recovery of peripheral blood counts had a favorable prognosis (HR for death, 0.52; 95% CI, 0.33–0.84).Discussion: These data align with findings from the pivotal VIALE‐A trial and support the use of HMA–VEN in patients unfit for intensive therapy.Keywords
This publication has 13 references indexed in Scilit:
- Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of CancerEuropean Journal of Cancer, 2023
- Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysisBlood Cancer Journal, 2022
- ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and AzacitidineBlood, 2022
- Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNBlood, 2022
- Acute myeloid leukemia: current progress and future directionsBlood Cancer Journal, 2021
- Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patientsAmerican Journal of Hematology, 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaNew England Journal of Medicine, 2020
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Acute myeloid leukemia in the real world: why population-based registries are neededBlood, 2012
- A note on quantifying follow-up in studies of failure timeControlled Clinical Trials, 1996